- CHMP anbefalede derfor, at der for Actira og tilknyttede navne (se bilag I) foretages ændring af
Characteristics sections 4.1, 4.2, 4.3, 4.4, 5.1 and 5.2 and Package Leaflet relevant sections as set out in Annex III for Actira and associated names (see Annex I).